Last reviewed · How we verify
EV71 Inactivated Vaccine — Competitive Intelligence Brief
phase 2
Infectious Diseases
Biologic
Live · refreshed every 30 min
Target snapshot
EV71 Inactivated Vaccine (EV71 Inactivated Vaccine) — Sinovac Biotech Co., Ltd. EV71 Inactivated Vaccine works by exposing the body to a small, harmless piece of the EV71 virus to stimulate the immune system to produce antibodies and provide immunity against future EV71 infections.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| EV71 Inactivated Vaccine TARGET | EV71 Inactivated Vaccine | Sinovac Biotech Co., Ltd | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- EV71 Inactivated Vaccine CI watch — RSS
- EV71 Inactivated Vaccine CI watch — Atom
- EV71 Inactivated Vaccine CI watch — JSON
- EV71 Inactivated Vaccine alone — RSS
Cite this brief
Drug Landscape (2026). EV71 Inactivated Vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/ev71-inactivated-vaccine. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing